SCHEMBL4356462

SCHEMBL4356462

Cc1cc(C(C)O)c2nc(N3CCOCC3)cc(=O)n2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 20/20 0.68
PIK3CA P42336 14/20 0.68
PIK3CD O00329 8/20 0.68
PIK3CG P48736 3/20 0.68
PIK3R1 P27986 1/20 0.68
CSNK1A1 P48729 1/20 0.68
PTK2 Q05397 1/20 0.68
CLK4 Q9HAZ1 1/20 0.68
SRC P12931 1/20 0.64
DDX6 P26196 1/20 0.64
PDE4A P27815 1/20 0.64
CSK P41240 1/20 0.64
MTOR P42345 1/20 0.64
PLK1 P53350 1/20 0.64
PRKDC P78527 1/20 0.64
PDE4B Q07343 1/20 0.64
PDE4C Q08493 1/20 0.64
PDE4D Q08499 1/20 0.64
AURKB Q96GD4 1/20 0.64
PI4KB Q9UBF8 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31314650 1.00 PIK3CB (0.68) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL24713661 0.88 PIK3CB (0.68) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL25364344 0.88 PIK3CA (0.63) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL24713579 0.87 PIK3CB (0.53) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL29160414 0.85 PIK3CB (0.72) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL30932918 0.84 PIK3CB (0.74) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL31179783 0.84 PIK3CB (0.65) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL24715035 0.83 PIK3CB (0.61) PIK3CBPIK3CAPIK3CDPIK3CG
SCHEMBL13759893 0.83 PIK3CB (0.68) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL23482795 0.82 PIK3CB (0.83) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731625-A1 NEW SYNTHESIS METHOD The Heart Research Institute Ltd (AU) 2026-04-29 EP disclosed
US-20250195532-A1 NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE THE CURATORS OF THE UNIVERSITY OF MISSOURI 2025-06-19 US disclosed
WO-2024259491-A1 NEW SYNTHESIS METHOD THE HEART RESEARCH INSTITUTE LTD (AU) 2024-12-26 WO disclosed
US-20240166617-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC (US) 2024-05-23 US disclosed
CN-117615763-A Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof 健道生物医药有限公司 2024-02-27 CN disclosed
EP-4284375-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Geode Therapeutics Inc. (US) 2023-12-06 EP disclosed
WO-2023173124-A1 NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE CHENG KUN (US) 2023-09-14 WO disclosed
WO-2022164812-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2022-08-04 WO disclosed
WO-2022164812-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2022-08-04 WO disclosed
US-20090191177-A1 Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 ASTRAZENECA AB (SE) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195532-A1 NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE PIK3C2B, PIK3CA, PIK3C2A PIK3CB 4/4885PIK3CA 2/4885PIK3CD 6/4885
US-20240166617-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF PIK3CA, PIK3CB, PI4KA PIK3CB 2/4885PIK3CA 1/4885PIK3CD 4/4885
US-20090191177-A1 Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 ITK, PI4KA, PIK3CA PIK3CB 9/4885PIK3CA 3/4885PIK3CD 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.